3rd Neuropsychiatric Drug Development

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

- Dive into novel therapeutic approaches for PTSD with Aptinyx, Bionomics, Tonix and MAPS 
- Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics and Intra-cellular Therapeutics
- Explore industry approaches for innovative trial design and new methods to modeling the placebo response with Novartis, Otsuka and Yale University
- Hear how pioneering biotechs are spearheading drug development for substance use disorders with Cerevel Therapeutics, Opiant Pharmaceuticals and NIDA
- Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda
- Uniting 80+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth, how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.

Others Details

URL: Brochure: https://go.evvnt.com/614469-3?pid=6581 Speakers: Gopi Shanker, Novartis Institutes for Biomedical Research, Seth Lederman, CEO and Chairman Tonix Pharmaceuticals, Steve Paul, Karuna Therapeutics, Inc, Kurt Rasmussen, The National Institute on Drug Abuse (NIDA), Patricio O'Donnell, Takeda Pharmaceuticals, Andy Kidd, Aptinyx, Errol De Souza, Bionomics, Phil Skolnick, Opiant, Jill Harkavy Friedman, American Foundation for Suicide Prevention and more. Time: 08:00 - 16:10